MGRX Mangoceuticals, Inc.
Healthcare$0.45+2.97%ClosedMarket Cap: $4.6M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
0.34
P/S
11.02
EV/EBITDA
-0.27
DCF Value
$0.08
FCF Yield
-106.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
52.4%
Operating Margin
-4203.8%
Net Margin
-4632.9%
ROE
-120.7%
ROA
-132.9%
ROIC
-126.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $67.9K | 42.7% | $-3.1M | $-3.4M | $— | — |
| Q4 null | $94.4K | 50.3% | $-1.5M | $-2.8M | $— | — |
| FY null | $456.0K | 54.9% | $-19.2M | $-20.6M | $— | — |
| Q3 null | $84.2K | 60.4% | $-7.5M | $-7.6M | $— | — |
| Q2 null | $168.1K | 53.5% | $-5.3M | $-5.4M | $— | — |
| Q1 null | $109.3K | 56.8% | $-4.9M | $-4.8M | $— | — |
| Q4 null | $105.2K | 76.1% | $-1.7M | $-1.9M | $— | — |
| FY null | $615.9K | 61.7% | $-8.0M | $-8.7M | $— | — |
| Q3 null | $133.4K | 62.0% | $-1.8M | $-2.0M | $— | — |
| Q2 null | $163.2K | 42.8% | $-2.2M | $-2.4M | $— | — |
| Q1 null | $214.1K | 68.8% | $-2.4M | $-2.4M | $— | — |
| Q4 2023 | $244.4K | 58.3% | $-2.6M | $-2.6M | $-1.98 | — |